Rosuvastatin Isomer-10-- (3S,5R,E)-tert-butyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoat
615263-60-0
Pharmaceutical Grade
90%
Shanghai Port or Shenzhen Port
H&D
A temperature-controlled box with a capacity of up to 10g
2025-01-26
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Product Description
-
Seller Information
-
DescriptionBasic Info
-
Product Name:
ent-Rosuvastatin tert-Butyl Ester
Other Name:ent-Rosuvastatin tert-Butyl Ester
CAS No.:615263-60-0
Molecular Formula:C26H36FN3O6S
InChIKeys:IJHZGLLGELSZAF-DSJWGCTQSA-N
Molecular Weight:537.6439432
Exact Mass:537.231
Categories:
Characteristics-
PSA:
138
XLogP3:2.9
Storage Conditions:-20°C Freezer, Under inert atmosphere
Hazard IdentificationClassification of the substance or mixture
no data available
GHS label elements, including precautionary statements
Pictogram(s) no data available Signal word no data available
Hazard statement(s) no data available
Precautionary statement(s) Prevention no data available
Response no data available
Storage no data available
Disposal no data available
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Drug impurity reference,Impurity reference,Reference substance,impurity
-
Location:
Hengfeng Wanda (Hubei) Pharmaceutical Technology Co., LTD., Hongshan District, Wuhan City, Hubei Province, China
-
Payment Terms:
TT against copy of documents,100% TT in advance
-
Average lead Time:
150 days
-
Total Annual Revenue:
$5 million-$10 million
-
Total Employees:
51-100
-
Year of Establishment:
2023
Company Certificates-
Brand certification certificate
-
QUALITY MANAGEMENT SYSTEM CERTIFICATE
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
More from this Seller
-
-
-
Upadacitinib Impurity 21-- (3R,4S)-benzyl 3-(2-chloroacetyl)-4-ethylpyrrolidine-1-carboxylate
Pharmaceutical Grade / 90%
-
-
-
-
Upadacitinib Impurity 1((3S,4S)-benzyl 3-(2-bromoacetyl)-4-ethylpyrrolidine-1-carboxylate)
Pharmaceutical Grade / 90%
-